icon-folder.gif   Conference Reports for NATAP  
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
More EASL Articles grey_arrow_rt.gif
Resistance Analyses Using Deep and Population Sequencing After 3 Day Monotherapy With GS-9669, a Novel Non-Nucleoside NS5B Inhibitor in Genotype 1 HCV Patients
  Reported by Jules Levin
EASL April 24-28 2013 Amsterdam
from Jules: the NNIs have received increasingly less attention in more recent years since the earlier days in earlier HCV drug development when they received quite a bit more attention. A major reason they received less attention is because they didnt fit into the notion of a potent 2 or 3 oral HCV drug regimen, which could be a PI, nucleotide & a NS5A, but now the NNI may be able to play an important role in certain select situations, they appear to be returning to attention. This NNI has potent activity in monotherapy, see link. A NNI with GT3 activity may be useful since at this EASL GT3 patients did not respond very well to regimens with a nucleotide or a NS5A.
GS-9669, A Novel NS5B Non-Nucleoside Thumb Site II Inhibitor, Demonstrates Potent Antiviral Activity, Favorable Safety Profile and Potential for Once-Daily
Nonclinical and Cross-genotypic Profiles of GS-9669, a Novel HCV NS5B Non-nucleoside Thumb Site II Inhibitor
Hadas Dvory-Sobol1, Evguenia S. Svarovskaia1, Viktoria Gontcharova1, Ross Martin1, Polina German1, Todd Appleby1, Eric J. Lawitz2, Michael D. Miller1, Hongmei Mo1 1Gilead Sciences, Inc., Foster City, CA, USA; 2Texas Liver Institute, University of Texas Health Science Center, San Antonio, USA